BioProspect's Termilone advances
The Australian biotechnology company, BioProspect (Brisbane, Queensland), hopes to receive Australian approval for its eremophilone oil-based termiticide, Termilone, within 12 months. The Australian Pesticides and Veterinary Medicines Authority has completed a preliminary assessment of the active ingredient, which qualifies for an eight-month review, BioProspect notes. The reduction from the 13 months for ais requiring greater toxicological assessment is an “excellent outcome”, says BioProspect’s chief executive officer, Peter May. It will result in reduced registration costs, he adds.